Lipid-lowering treatment and inflammatory mediators in diabetes and chronic kidney disease

January 15, 2014

Tora Almquist et al. European Journal of Clinical Investigation. Doi: 10.1111/eci.12230

This study on 18 patients with diabetes compared the effects of simvastatin alone (S) or simvastatin+ ezetimibe (S+E) in a randomized, double-blind, cross-over study on inflammatory parameters.

It found that patients with CKD stages 3-4 had increased inflammatory activity compared to patients with normal GFR.

Lipid-lowering treatment decreased the levels of monocyte chemoattractant protein-1 and interferon gamma in patients with concomitant CKD [monocyte chemoattractant protein-1 (MCP-1) facilitates the recruitment of monocytes into atherosclerotic lesions and is involved in diabetic nephropathy.

Interferon gamma is important in atherosclerosis and increases the synthesis of chemokines including MCP-1].

The authors posit that because inflammation may contribute to the high cardiovascular risk in diabetes mellitus and chronic kidney disease this treatment may be beneficial with regard to the progression of both atherosclerosis and diabetic nephropathy.

Article information
Topic:
News
Author:
Source:
European Journal of Clinical Investigation
Added:
Jan 15, 2014
Free HCP newsletter
Join the newsletter
Free weekly news
Latest diabetes healthcare news direct to your inbox.
Email:
Profession:
NHS employee:
Latest forum posts
The latest forum threads from the Ask a Question forum.
Healthcare Search